Back to Search
Start Over
Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity:an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers
- Source :
- Jansen , M , Schmidt , A F , Jans , J J M , Christiaans , I , van der Crabben , S N , Hoedemaekers , Y M , Dooijes , D , Jongbloed , J D H , Boven , L G , Lekanne Deprez , R H , Wilde , A A M , van der Velden , J , de Boer , R A , van Tintelen , J P , Asselbergs , F W & Baas , A F 2023 , ' Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity : an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers ' , Journal of Cardiovascular Translational Research , vol. 16 , no. 6 , pp. 1267-1275 .
- Publication Year :
- 2023
-
Abstract
- Hypertrophic cardiomyopathy (HCM) is a relatively common genetic heart disease characterised by myocardial hypertrophy. HCM can cause outflow tract obstruction, sudden cardiac death and heart failure, but severity is highly variable. In this exploratory cross-sectional study, circulating acylcarnitines were assessed as potential biomarkers in 124 MYBPC3 founder variant carriers (59 with severe HCM, 26 with mild HCM and 39 phenotype-negative [G + P-]). Elastic net logistic regression identified eight acylcarnitines associated with HCM severity. C3, C4, C6-DC, C8:1, C16, C18 and C18:2 were significantly increased in severe HCM compared to G + P-, and C3, C6-DC, C8:1 and C18 in mild HCM compared to G + P-. In multivariable linear regression, C6-DC and C8:1 correlated to log-transformed maximum wall thickness (coefficient 5.01, p = 0.005 and coefficient 0.803, p = 0.007, respectively), and C6-DC to log-transformed ejection fraction (coefficient -2.50, p = 0.004). Acylcarnitines seem promising biomarkers for HCM severity, however prospective studies are required to determine their prognostic value. Graphical abstract: [Figure not available: see fulltext.].
Details
- Database :
- OAIster
- Journal :
- Jansen , M , Schmidt , A F , Jans , J J M , Christiaans , I , van der Crabben , S N , Hoedemaekers , Y M , Dooijes , D , Jongbloed , J D H , Boven , L G , Lekanne Deprez , R H , Wilde , A A M , van der Velden , J , de Boer , R A , van Tintelen , J P , Asselbergs , F W & Baas , A F 2023 , ' Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity : an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers ' , Journal of Cardiovascular Translational Research , vol. 16 , no. 6 , pp. 1267-1275 .
- Notes :
- application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1390850182
- Document Type :
- Electronic Resource